Abiopharma

🔍 Farrow Jeffrey S (Executive)

Company: Tarsus Pharmaceuticals, Inc. (TARS)

Report Date: 2026-03-17

Detailed Transactions and Holdings:

• Sold 2,111 shares of Common Stock at $69.42 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 47,635.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,133 shares of Common Stock at $68.71 per share (Direct)
  Date: 2026-03-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 45,502.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,186 shares of Common Stock at $67.0 per share (Direct)
  Date: 2026-03-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 43,316.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
• REMARKS: Chief Financial Officer and Chief Strategy Officer